The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

Joaquim Gea; Sergi Pascual; Ady Castro-Acosta; Carmen Hernández-Carcereny; Robert Castelo; Eduardo Márquez-Martín; Concepción Montón; Alexandre Palou; Rosa Faner; Laura I. Furlong; Luis Seijo; Ferran Sanz; Montserrat Torà; Carles Vilaplana; Carme Casadevall; José Luis López-Campos; Eduard Monsó; Germán Peces-Barba; Borja G. Cosío; Alvar Agustí; Mireia Admetlló; Carlos Alvarez-Martínez; Esther Barreiro; Ferran Casals; Rocío Córdova; Marian García; José G. González-García; Eduardo Márquez; Miren Josune Ormaza; Pau Puigdevall; Luis Seijo; Yolanda Torralba

doi:10.1016/j.arbres.2018.07.026

The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

Joaquim Gea, Sergi Pascual, Ady Castro-Acosta, Carmen Hernández-Carcereny, Robert Castelo, Eduardo Márquez-Martín, Concepción Montón, Alexandre Palou, Rosa Faner, Laura I. Furlong, Luis Seijo, Ferran Sanz, Montserrat Torà, Carles Vilaplana, Carme Casadevall, José Luis López-Campos, Eduard Monsó, Germán Peces-Barba, Borja G. Cosío, Alvar AgustíMireia Admetlló, Carlos Alvarez-Martínez, Esther Barreiro, Ferran Casals, Rocío Córdova, Marian García, José G. González-García, Eduardo Márquez, Miren Josune Ormaza, Pau Puigdevall, Luis Seijo, Yolanda Torralba

Department of Medicine

Research output: Contribution to journal › Article › Research

15 Citations (Scopus)

Abstract

© 2018 SEPAR Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain ‘omics’ (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients.

Original language	English
Pages (from-to)	93-99
Journal	Archivos de Bronconeumologia
Volume	55
DOIs	https://doi.org/10.1016/j.arbres.2018.07.026
Publication status	Published - 1 Feb 2019

Keywords

Biological markers
COPD
Endotypes
Multilevel analysis
Personalized medicine

Access to Document

10.1016/j.arbres.2018.07.026

Cite this

Gea, J., Pascual, S., Castro-Acosta, A., Hernández-Carcereny, C., Castelo, R., Márquez-Martín, E., Montón, C., Palou, A., Faner, R., Furlong, L. I., Seijo, L., Sanz, F., Torà, M., Vilaplana, C., Casadevall, C., López-Campos, J. L., Monsó, E., Peces-Barba, G., Cosío, B. G., ... Torralba, Y. (2019). The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologia, 55, 93-99. https://doi.org/10.1016/j.arbres.2018.07.026

@article{bcefa3b4afe5465b99dd4ea732b3dfdd,

title = "The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease",

abstract = "{\textcopyright} 2018 SEPAR Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain {\textquoteleft}omics{\textquoteright} (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients.",

keywords = "Biological markers, COPD, Endotypes, Multilevel analysis, Personalized medicine",

author = "Joaquim Gea and Sergi Pascual and Ady Castro-Acosta and Carmen Hern{\'a}ndez-Carcereny and Robert Castelo and Eduardo M{\'a}rquez-Mart{\'i}n and Concepci{\'o}n Mont{\'o}n and Alexandre Palou and Rosa Faner and Furlong, {Laura I.} and Luis Seijo and Ferran Sanz and Montserrat Tor{\`a} and Carles Vilaplana and Carme Casadevall and L{\'o}pez-Campos, {Jos{\'e} Luis} and Eduard Mons{\'o} and Germ{\'a}n Peces-Barba and Cos{\'i}o, {Borja G.} and Alvar Agust{\'i} and Mireia Admetll{\'o} and Carlos Alvarez-Mart{\'i}nez and Esther Barreiro and Ferran Casals and Roc{\'i}o C{\'o}rdova and Marian Garc{\'i}a and Gonz{\'a}lez-Garc{\'i}a, {Jos{\'e} G.} and Eduardo M{\'a}rquez and Ormaza, {Miren Josune} and Pau Puigdevall and Luis Seijo and Yolanda Torralba",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/j.arbres.2018.07.026",

language = "English",

volume = "55",

pages = "93--99",

}

Gea, J, Pascual, S, Castro-Acosta, A, Hernández-Carcereny, C, Castelo, R, Márquez-Martín, E, Montón, C, Palou, A, Faner, R, Furlong, LI, Seijo, L, Sanz, F, Torà, M, Vilaplana, C, Casadevall, C, López-Campos, JL, Monsó, E, Peces-Barba, G, Cosío, BG, Agustí, A, Admetlló, M, Alvarez-Martínez, C, Barreiro, E, Casals, F, Córdova, R, García, M, González-García, JG, Márquez, E, Ormaza, MJ, Puigdevall, P, Seijo, L & Torralba, Y 2019, 'The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease', Archivos de Bronconeumologia, vol. 55, pp. 93-99. https://doi.org/10.1016/j.arbres.2018.07.026

TY - JOUR

T1 - The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

AU - Gea, Joaquim

AU - Pascual, Sergi

AU - Castro-Acosta, Ady

AU - Hernández-Carcereny, Carmen

AU - Castelo, Robert

AU - Márquez-Martín, Eduardo

AU - Montón, Concepción

AU - Palou, Alexandre

AU - Faner, Rosa

AU - Furlong, Laura I.

AU - Seijo, Luis

AU - Sanz, Ferran

AU - Torà, Montserrat

AU - Vilaplana, Carles

AU - Casadevall, Carme

AU - López-Campos, José Luis

AU - Monsó, Eduard

AU - Peces-Barba, Germán

AU - Cosío, Borja G.

AU - Agustí, Alvar

AU - Admetlló, Mireia

AU - Alvarez-Martínez, Carlos

AU - Barreiro, Esther

AU - Casals, Ferran

AU - Córdova, Rocío

AU - García, Marian

AU - González-García, José G.

AU - Márquez, Eduardo

AU - Ormaza, Miren Josune

AU - Puigdevall, Pau

AU - Seijo, Luis

AU - Torralba, Yolanda

PY - 2019/2/1

Y1 - 2019/2/1

N2 - © 2018 SEPAR Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain ‘omics’ (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients.

AB - © 2018 SEPAR Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain ‘omics’ (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients.

KW - Biological markers

KW - COPD

KW - Endotypes

KW - Multilevel analysis

KW - Personalized medicine

U2 - 10.1016/j.arbres.2018.07.026

DO - 10.1016/j.arbres.2018.07.026

M3 - Article

C2 - 30343952

VL - 55

SP - 93

EP - 99

ER -

The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this